Use of the agarose gel method to identify and quantitate factor VIII:C inhibitors. 1985

P G Cassidy, and D A Triplett, and F M LaDuca

The agarose gel method for the detection and quantitation of Factor VIII inhibitors was investigated and compared with the Bethesda method. The agarose gel method was standardized for this study by modifications of the original method of Bird. (Bird P: Coagulation in an agarose gel and its application to the detection and measurement of factor VIII antibodies. Br J Haematol 1975; 29:329-340) Precision studies on values obtained by the agarose gel method indicated it is a reproducible assay. Random error was evident in both methods, but variance appeared to be greater in the Bethesda method for most of the samples evaluated. Comparison of the two methods with split patient samples indicated that proportional error is present in the agarose gel method, and that standardization of the method requires additional study. The agarose gel assay detected low levels of inhibitor (down to 3.4 Bethesda units) and all positive samples were identified. A screening procedure modification of the agarose gel method provided the sensitivity to detect Factor VIII inhibitor levels of less than 1.0 Bethesda units. The results indicated that the agarose gel method is a feasible alternative to the Bethesda method for both quantitative and qualitative determination of Factor VIII inhibitors. Furthermore, since reproducibility is better, it may be useful in detecting the "true" fluctuations of inhibitor titers in a given patient.

UI MeSH Term Description Entries
D008722 Methods A series of steps taken in order to conduct research. Techniques,Methodological Studies,Methodological Study,Procedures,Studies, Methodological,Study, Methodological,Method,Procedure,Technique
D010314 Partial Thromboplastin Time The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy. Activated Partial Thromboplastin Time,Cephalin-Kaolin Coagulation Time,Kaolin-Cephalin Coagulation Time,Thromboplastin Time, Partial,Coagulation Time, Cephalin-Kaolin,Cephalin Kaolin Coagulation Time,Coagulation Time, Cephalin Kaolin,Coagulation Time, Kaolin-Cephalin,Kaolin Cephalin Coagulation Time
D011517 Prothrombin Time Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS. Quick Test,Russell's Viper Venom Time,Thrombotest,Russell Viper Venom Time,Russells Viper Venom Time,Prothrombin Times,Test, Quick,Time, Prothrombin,Times, Prothrombin
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D005782 Gels Colloids with a solid continuous phase and liquid as the dispersed phase; gels may be unstable when, due to temperature or other cause, the solid phase liquefies; the resulting colloid is called a sol.
D006467 Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage. Factor VIII Deficiency,Hemophilia,Autosomal Hemophilia A,Classic Hemophilia,Deficiency, Factor VIII,Factor 8 Deficiency, Congenital,Factor VIII Deficiency, Congenital,Haemophilia,Hemophilia A, Congenital,Hemophilia, Classic,As, Autosomal Hemophilia,Autosomal Hemophilia As,Classic Hemophilias,Congenital Hemophilia A,Congenital Hemophilia As,Hemophilia A, Autosomal,Hemophilia As,Hemophilia As, Autosomal,Hemophilia As, Congenital,Hemophilias, Classic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012685 Sepharose Agarose,Sepharose 4B,Sepharose C1 4B,4B, Sepharose C1,C1 4B, Sepharose
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

P G Cassidy, and D A Triplett, and F M LaDuca
May 1996, American journal of hematology,
P G Cassidy, and D A Triplett, and F M LaDuca
January 1980, Methods in enzymology,
P G Cassidy, and D A Triplett, and F M LaDuca
January 1996, Acta haematologica,
P G Cassidy, and D A Triplett, and F M LaDuca
November 1991, The American journal of medicine,
P G Cassidy, and D A Triplett, and F M LaDuca
October 1982, American journal of clinical pathology,
P G Cassidy, and D A Triplett, and F M LaDuca
January 1976, S & TA & NU. Rivista di scienza e tecnologia degli alimenti e di nutrizione umana,
P G Cassidy, and D A Triplett, and F M LaDuca
February 1981, British journal of haematology,
Copied contents to your clipboard!